WHO ICTRP trial
Phase I/II Study of Combination Therapy With MRA (Tocilizumab) and Gemcitabine…
JPRN-jRCT2080220858 · Japan Primary Registries Network (JPRN)
Key facts
| Trial ID | JPRN-jRCT2080220858 |
|---|---|
| Public title | Phase I/II Study of Combination Therapy With MRA (Tocilizumab) and Gemcitabine for Unresectable Locally Advanced or Metastatic Pancreatic Cancer |
| Scientific title | Phase I/II Study of Combination Therapy With MRA (Tocilizumab) and Gemcitabine for Unresectable Locally Advanced or Metastatic Pancreatic Cancer |
| Primary sponsor | Chugai Pharmaceutical Co., Ltd. |
| Registry | Japan Primary Registries Network (JPRN) |
| Study type | Interventional |
| Phase | 1-2 |
| Conditions | unresectable locally advanced or metastatic pancreatic cancer |
| Interventions | investigational material(s) Generic name etc : MRA INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : 8 mg/kg, every 2 weeks |
| Registration date | Sep 14, 2009 |
| Target size | 30 |
| Secondary IDs | JapicCTI-090889 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: